Latest Security News

Titan Minerals has made significant strides in its Ecuadorian copper and gold projects, securing a $20 million capital raise and progressing key drilling milestones under a major joint venture agreement.

Coda Minerals has significantly enhanced the economic outlook of its Elizabeth Creek Copper-Cobalt Project, with a pre-tax NPV7 rising to $1.18 billion and a post-tax NPV7 increase of 57% to $802 million. The company also secured $5.1 million in fresh capital to accelerate exploration and drilling activities in 2025.

Arika Resources has expanded its exploration footprint at the Yundamindra Gold Project with over 25 new high-priority gold targets identified and a $3.2 million capital raise to fast-track drilling programs. The company awaits assay results from recent drilling that could redefine the project's scale.

Mastermyne Group Limited reported a 14% rise in EBITDA to $4.1 million for FY25 Q2, even as revenue fell 10% due to operational disruptions at Anglo American’s Grosvenor mine. The company secured key contract extensions and maintained a strong cash position, positioning itself for growth amid sector uncertainties.

Patriot Lithium Limited has made significant strides in acquiring and exploring copper projects in Zambia while navigating complex negotiations for its key Gorman Lithium Project in Canada.

Core Energy Minerals Ltd has fortified its uranium exploration ambitions with a $3.7 million capital raise and strategic acquisitions in South Australia, setting the stage for a busy 2025 exploration calendar.

Peninsula Energy has delayed commissioning of its Lance Uranium Project’s Central Processing Plant to mid-2025, prompting a likely downgrade in annual production guidance amid ongoing operational challenges.

Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.